SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. (OTCBB:MCET), developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, today announced that co-administration of MCT-465, a Toll-like Receptor (TLR) agonist, with the Company’s patented antigen presenting immunoglobulin therapeutic resulted in the control of primary tumor growth, induced the immune system to completely destroy the tumors, and ultimately prevented morbidity and mortality in 60 percent of treated animals.
